Natalia Salinas Parra

Dr. Natalia Salinas Parra

Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Mississippi, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Natalia Salinas ParraNatalia Salinas Parra
Natalia Salinas Parra
HRHeather M. Ross
Heather M. Ross
AKAdnan Khan
Adnan Khan
MWMarisa Wu
Marisa Wu
RGRisa Goldberg
Risa Goldberg
DHDina Halegoua-DeMarzio
Dina Halegoua-DeMarzio
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, with increasing global incidence. Morbidity and mortality associated with HCC remains high, and HCC is the leading cause of cancer death worldwide. Early detection and treatment of HCC can increase five-year survival by over 60%. Detection of HCC remains challenging, however, as HCC arises from a variety of environmental, genetic, and viral etiologies, and it demonstrates a complex pathophysiology and displays a heterogeneous morphology. Current diagnostic methods rely on abdominal ultrasound with or without concurrent AFP biomarker testing for high-risk individuals. This review provides an overview of HCC diagnostic modalities and highlights the promising nature of translational developments in biomarkers, next generation sequencing (NGS), artificial intelligence, molecular imaging, and liquid biopsy for earlier and more accurate diagnosis of HCC. Furthermore, we identify areas for improvement that must be addressed before the widespread usage and implementation of these methods.

24 August 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JHJames J. Hoy
James J. Hoy
Natalia Salinas ParraNatalia Salinas Parra
Natalia Salinas Parra
JPJeannie Park
Jeannie Park
SKSkyler Kuhn
Skyler Kuhn
RIRamiro Iglesias‐Bartolome
Ramiro Iglesias‐Bartolome
The PKA‐inhibitor (PKI) family members PKIα, PKIβ, and PKIγ bind with high affinity to PKA and block its kinase activity, modulating the extent, and duration of PKA‐mediated signaling events. While PKA is a well‐known regulator of physiological and oncogenic events, the role of PKI proteins in these pathways has remained elusive. Here, by measuring activation of the MAPK pathway downstream of GPCR‐Gαs‐cAMP signaling, we show that the expression levels of PKI proteins can alter the balance of activation of two major cAMP targets: PKA and EPAC. Our results indicate that PKA maintains repressive control over MAPK signaling as well as a negative feedback on cAMP concentration. Overexpression of PKI and its subsequent repression of PKA dysregulates these signaling pathways, resulting in increased intracellular cAMP, and enhanced activation of EPAC and MAPK. We also find that amplifications of PKIA are common in prostate cancer and are associated with reduced progression free survival. Depletion of PKIA in prostate cancer cells leads to reduced migration, increased sensitivity to anoikis and reduced tumor growth. By altering PKA activity PKI can act as a molecular switch, driving GPCR‐Gαs‐cAMP signaling toward activation of EPAC‐RAP1 and MAPK, ultimately modulating tumor growth.

1 January 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YYYao Yuan
Yao Yuan
Natalia Salinas ParraNatalia Salinas Parra
Natalia Salinas Parra
QCQianming Chen
Qianming Chen
RIRamiro Iglesias-Bartolome
Ramiro Iglesias-Bartolome

2 August 2022 in Livers
Verified
Journal Article
Open access
PDF file
AKAdnan Khan
Adnan Khan
KCKashyap Rajendra Chauhan
Kashyap Rajendra Chauhan
HRHeather Ross
Heather Ross
Natalia Salinas ParraNatalia Salinas Parra
Natalia Salinas Parra
JMJohn Magagna
John Magagna
DHDina Halegoua-DeMarzio
Dina Halegoua-DeMarzio
Herbal and dietary supplement (HDS) use has grown exponentially in the United States. Unfortunately, the incidence of HDS-related liver injury has proportionally increased. Despite the potential for certain HDSs to cause clinically significant liver injury, they are not regulated by the Food and Drug Administration. Recent efforts have been made to regulate HDSs but are far removed from the scrutiny of prescription medications. Scant literature exists on HDSs and their risks of causing liver injury. In this comprehensive review, we examine trends of HDS use in the United States and the pathophysiologic mechanisms of drug-induced liver injury (DILI) of certain HDSs. Finally, we review usage rates; benefits, if any; purported pathophysiology of DILI; and propensity for progression to fulminant hepatic failure of nine HDSs linked to clinically significant DILI.


10 April 2023 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
Jacob BeirigerJacob Beiriger
Jacob Beiriger
AKAdnan Khan
Adnan Khan
BYBrian Yan
Brian Yan
HRHeather Ross
Heather Ross
MWMakala Wang
Makala Wang
AGAlexis Gerber
Alexis Gerber
Pancreatitis is a condition that causes inflammation in the pancreas, an organ located behind the stomach. This condition often presents as neuropathic, inflammatory, and/or visceral pain. Acute pancreatitis is typically characterized by sudden and severe abdominal pain, often in the upper right part of the abdomen. The pain from pancreatitis can be caused by different mechanisms, such as abnormal activation of pancreatic zymogens or NF-κB mediated inflammation in the pancreas. The treatment of pancreatitis depends on its type, severity, and underlying cause. Hospitalization and medications are typically necessary, while in others, surgery may be required. Proper management of pancreatitis is essential, as it can help reduce the risk of complications and improve the patient’s quality of life. The literature on pancreatitis pain management evaluates systematic approaches and the effectiveness of various treatments, such as lidocaine, opioid agonists, ketamine, magnesium, endoscopic methods, spinal cord stimulation, and other novel treatments present opportunities for exploration in pancreatitis pain management.